Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis

• Published in: Acta biomaterialia 2021-11, Vol.135, p.567-581
• Main Authors: Hu, Shichuan, Ma, Jinhu, Su, Chao, Chen, Yanwei, Shu, Yongheng, Qi, Zhongbing, Zhang, Bin, Shi, Gang, Zhang, Yan, Zhang, Yuwei, Huang, Anliang, Kuang, Yueting, Cheng, Ping
• Format: Article
• Language: English
• Subjects: Anticancer properties; Antigen (tumor-associated); Antigens; Antitumor activity; Breast cancer; Cancer; Cancer vaccines; Cancer-associated fibroblasts; Colon; Cytotoxicity; Drug resistance; Exosome-like vaccine; Exosomes; FAP; Ferroptosis; Fibroblast activation protein; Fibroblasts; Immune response; Immune response (cell-mediated); Immunity; Immunosuppression; Immunotherapy; Interferon; Lung cancer; Lymphocytes; Lymphocytes T; Melanoma; Metastases; Parenchyma; Solid tumors; Stromal cells; Tumor cells; Tumor microenvironment; Tumors; Vaccines; γ-Interferon
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2021.09.003

Tumor vaccines that induce effective and sustained antitumor immunity are highly promising for cancer therapy. However, the antitumor potential of these vaccines is weakened due to the immunosuppressive characteristics of the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells within the TME; they play an important role in tumor growth, metastasis, immunosuppression, and drug resistance. Fibroblast activation protein-α (FAP) is overexpressed in CAFs in more than 90% of human tumor tissues. Further, FAP+CAFs are an ideal interstitial target for the immunotherapy of solid tumors. Exosomes derived from tumor cells contain many tumor antigens, which can be used as the basis of tumor vaccines that elicit strong antitumor immunity. Almost all exosome-based cancer vaccines have been designed and developed for tumor parenchymal cells. Moreover, the exosome production is very low and the purification is very difficult, limiting their clinical application as tumor vaccines. In this study, we developed FAP gene–engineered tumor cell–derived exosome-like nanovesicles (eNVs-FAP) as a tumor vaccine that can be prepared easily and in large quantities. The eNVs-FAP vaccine inhibited tumor growth by inducing strong and specific cytotoxic T lymphocyte (CTL) immune responses against tumor cells and FAP+CAFs and reprogramming the immunosuppressive TME in the colon, melanoma, lung, and breast cancer models. Moreover, eNVs-FAP vaccine–activated cellular immune responses could promote tumor ferroptosis by releasing interferon-gamma (IFN-γ) from CTLs and depleting FAP+CAFs. Thus, eNVs-FAP is a candidate tumor vaccine targeting both the tumor parenchyma and the stroma. Nanovaccines can activate immune cells and promote an antitumor immune response. In this study, we developed the fibroblast activation protein-α (FAP) gene–engineered tumor cell–derived exosome-like vesicle vaccines (eNVs-FAP). A large number of eNVs-FAP were obtained by continuously squeezing FAP gene–engineered tumor cells. eNVs-FAP showed excellent antitumor effects in a variety of tumor-bearing mouse models. The mechanistic analysis showed that eNVs-FAP promoted the maturation of dendritic cells (DCs), increased the infiltration of effector T cells into target tumor cells and FAP-positive cancer-associated fibroblasts (FAP+CAFs), and reduced the proportion of immunosuppressive cells, including M2-like tumor-associated macrophages (M2-TAMs), myeloid-derived suppr